Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $433168.0.

  • Century Therapeutics' Gains from Sales and Divestitures rose 165151.83% to $433168.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $433168.0, marking a year-over-year increase of 165151.83%. This contributed to the annual value of $1.5 million for FY2024, which is 146149.65% up from last year.
  • As of Q3 2025, Century Therapeutics' Gains from Sales and Divestitures stood at $433168.0, which was up 165151.83% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Gains from Sales and Divestitures peaked at $1.5 million during Q4 2024, and registered a low of $24685.0 during Q1 2024.
  • For the 4-year period, Century Therapeutics' Gains from Sales and Divestitures averaged around $350412.9, with its median value being $161159.0 (2022).
  • Per our database at Business Quant, Century Therapeutics' Gains from Sales and Divestitures crashed by 8038.35% in 2023 and then soared by 396158.4% in 2025.
  • Century Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $488758.0 in 2022, then plummeted by 80.38% to $95877.0 in 2023, then soared by 1461.5% to $1.5 million in 2024, then plummeted by 71.07% to $433168.0 in 2025.
  • Its last three reported values are $433168.0 in Q3 2025, $1.0 million for Q2 2025, and $484190.0 during Q1 2025.